Tags

Type your tag names separated by a space and hit enter

Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic.
Rev Esp Enferm Dig 2015; 107(12):767-8RE

Abstract

Ciprofloxacin and amoxicillin/clavulanic are two widely used antibiotics due to their high efficacy and few side effects. While the percentage of hepatotoxicity of these antibiotics is low, their frequent use has led to a progressive increase in the number of cases. Both antibiotics have been associated with a wide variety of hepatotoxic reactions, from a slight rise of transaminases to fulminant hepatitis. Once hepatotoxicity secondary to a drug appears, the first step is to discontinue the drug. Physicians may opt to administer an alternative treatment with a different chemical structure. It should be borne in mind, however, that different chemical structures may also cause recurrent drug-induced liver injuries (DILI). We present the case of a patient who consecutively developed DILI due to ciprofloxacin and amoxicillin/clavulanic.

Authors+Show Affiliations

Medicina Interna, Corporació Sanitària i Universitària Parc Taulí, España.Hepatología, Corporació Sanitària i Universitària ParcTaulí, España.Hepatología, Parc Tauli Sabadell. Hospital Universitari, Espana.Hepatología, Parc Tauli Sabadell. Hospital Universitari., españa.Hepatología, Parc Tauli Sabadell. Hospital Universitari, España.Hepatología, Parc Tauli Sabadell. Hospital Universitari., España.

Pub Type(s)

Case Reports
Letter

Language

eng

PubMed ID

26671593

Citation

Moreno, Luís, et al. "Recurrent Drug-induced Liver Injury (DILI) With Ciprofloxacin and Amoxicillin/clavulanic." Revista Espanola De Enfermedades Digestivas : Organo Oficial De La Sociedad Espanola De Patologia Digestiva, vol. 107, no. 12, 2015, pp. 767-8.
Moreno L, Sánchez-Delgado J, Vergara M, et al. Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic. Rev Esp Enferm Dig. 2015;107(12):767-8.
Moreno, L., Sánchez-Delgado, J., Vergara, M., Casas, M., Miquel, M., & Dalmau, B. (2015). Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic. Revista Espanola De Enfermedades Digestivas : Organo Oficial De La Sociedad Espanola De Patologia Digestiva, 107(12), pp. 767-8.
Moreno L, et al. Recurrent Drug-induced Liver Injury (DILI) With Ciprofloxacin and Amoxicillin/clavulanic. Rev Esp Enferm Dig. 2015;107(12):767-8. PubMed PMID: 26671593.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic. AU - Moreno,Luís, AU - Sánchez-Delgado,Jordi, AU - Vergara,Mercedes, AU - Casas,Meritxell, AU - Miquel,Mireia, AU - Dalmau,Blai, PY - 2015/12/17/entrez PY - 2015/12/17/pubmed PY - 2017/1/20/medline SP - 767 EP - 8 JF - Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva JO - Rev Esp Enferm Dig VL - 107 IS - 12 N2 - Ciprofloxacin and amoxicillin/clavulanic are two widely used antibiotics due to their high efficacy and few side effects. While the percentage of hepatotoxicity of these antibiotics is low, their frequent use has led to a progressive increase in the number of cases. Both antibiotics have been associated with a wide variety of hepatotoxic reactions, from a slight rise of transaminases to fulminant hepatitis. Once hepatotoxicity secondary to a drug appears, the first step is to discontinue the drug. Physicians may opt to administer an alternative treatment with a different chemical structure. It should be borne in mind, however, that different chemical structures may also cause recurrent drug-induced liver injuries (DILI). We present the case of a patient who consecutively developed DILI due to ciprofloxacin and amoxicillin/clavulanic. SN - 1130-0108 UR - https://www.unboundmedicine.com/medline/citation/26671593/Recurrent_drug_induced_liver_injury__DILI__with_ciprofloxacin_and_amoxicillin/clavulanic_ L2 - https://online.reed.es/Revistas/REED_2015_107_12/Contenido/pdf/vol107num12_en_11.pdf DB - PRIME DP - Unbound Medicine ER -